Thermo Fisher Scientific Expands Bioproduction Capacity in Greater Boston
Thermo Fisher Scientific Inc. (Massachusetts, USA) has opened a new biomanufacturing facility in Chelmsford, Massachusetts. The $160 million, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production capabilities.
“This market continues to grow, and the world’s leading biopharmaceutical companies depend on our technologies, services, and expertise to help deliver life-changing therapies to patients,” said Jean Luo, VP and General Manager, Purification and Pharma Analytics, Thermo Fisher Scientific.
The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments can reach more patients faster.
“The Chelmsford site will help us provide our customers with the critical resin materials they need as they scale up production and bring new innovations to market,” continued Luo. “This ultimately helps ensure more patients get the treatments they need faster.”
When fully staffed, the Chelmsford site will employ up to 250 people and will be part of Thermo Fisher’s global bioprocessing supply network.
For more information, please visit: www.thermofisher.com
Hydrophilic Interaction Liquid Chromatography for Oligonucleotide Therapeutics: Method Consideration
March 10th 2025Hydrophilic interaction liquid chromatography (HILIC) has emerged as a promising alternative to traditional ion-pair reversed phase liquid chromatography (IP-RPLC) methods for separating oligonucleotides (ON). This work investigates the application of HILIC to the separation of ON sequence and length variants, duplexes, and single-stranded components.
Matrix Effects on Quantitation in Liquid Chromatography: Sources and Solutions
March 10th 2025The “matrix effect” is one of the sticky details that can make the use of liquid chromatography (LC) for quantitative purposes challenging, even though it is conceptually quite straightforward. In this installment of LC Troubleshooting, Dwight Stoll reviews what is being referred to during talks about “matrix effects”, and discusses some of the potential origins of the phenomenon in practice.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
